Abstract
Objective: To assess the symptom severity of autonomic nervous system (ANS) impairment in individuals with idiopathic hypersomnia (IH).
Background: ANS impairment has been reported in other central nervous system hypersomnias, however data on ANS impairment in IH are limited.
Design/Methods: 272 participants with IH and 145 healthy controls completed a battery of online questionnaires including the Composite Autonomic Symptom Score 31 (COMPASS 31), Epworth Sleep Scale (ESS), Morningness-Eveningness Questionnaire (MEQ-SA), Chalder Fatigue Questionnaire (CFQ), Insomnia Severity Index (ISI), RLS single item screen, STOP-Bang Questionnaire, and the RAND 36-Item Health Survey (RAND-36). A descriptive analysis was performed to assess for differences in scores between groups and to assess correlations among individual questionnaires. Because scores were not normally distributed for any measure, median and inter-quartile range are reported, and continuous measures were compared by Wilcoxon rank sum. Participants were identified as cases if they self-reported a formal diagnosis of IH by a physician. All subjects were recruited through the Hypersomnia Foundation website.
Results: Participants with IH reported significantly higher COMPASS 31 scores (30 [25–36] vs. 20 [16.7–23]; p<0.001, d=1.42). IH participants also reported higher ESS scores (16 [13–19] vs. 6 [4–9]; p<0.001, d=2.18) and CFQ scores (30 [26–34] vs. 14 [13–18]; p<0.001, d=2.09). Consistent with these group-wise differences, COMPASS 31 scores showed a strong positive correlation with both ESS (r=0.61, p<0.001) and CFQ (r=0.63, p<0.001) scores.
Conclusions: Symptoms of ANS impairment, sleepiness, and fatigue are more severe in individuals with IH compared to controls. Moreover, ANS symptom burden correlates moderately with higher levels of sleepiness and fatigue. Future analysis will focus on COMPASS subscores and objective autonomic testing to help identify symptomatic domains, with the goal of more focused therapeutic targets for patients with IH.
Disclosure: Dr. Kim has nothing to disclose. Dr. Cheung has nothing to disclose. Dr. Schneider has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals and Hatch Baby. Dr. Schneider holds stock and/or stock options in Knit Health, Inc.. Dr. Trotti has nothing to disclose. Dr. Miglis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck, Schlesinger Associates, Defined Health, Elsevier.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg